Literature DB >> 23183106

Pathophysiological relevance of the cardiac β2-adrenergic receptor and its potential as a therapeutic target to improve cardiac function.

Joaquín Pérez-Schindler1, Andrew Philp, Jesús Hernandez-Cascales.   

Abstract

β-adrenoceptors are members of the G protein-coupled receptor superfamily which play a key role in the regulation of myocardial function. Their activation increases cardiac performance but can also induce deleterious effects such as cardiac arrhythmias or myocardial apoptosis. In fact, inhibition of β-adrenoceptors exerts a protective effect in patients with sympathetic over-stimulation during heart failure. Although β(2)-adrenoceptor is not the predominant subtype in the heart, it seems to importantly contribute to the cardiac effects of adrenergic stimulation; however, the mechanism by which this occurs is not fully understood. This review summarizes the current knowledge on the role of β(2)-adrenoceptors in the regulation of cardiac contractility, metabolism, cardiomyocyte survival and cardiac arrhythmias. In addition, therapeutic considerations relating to stimulation of the β(2)-adrenoceptor such as an increase in cardiac contractility with low arrythmogenic effect, protection of the myocardium again apoptosis or positive regulation of heart metabolism are discussed.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23183106     DOI: 10.1016/j.ejphar.2012.11.001

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  An endogenous sensitizer of β adrenergic receptors and its analogs attenuate the inhibition of β adrenergic receptors by propranolol and atenolol in the rat myocardium.

Authors:  V I Tsirkin; A D Nozdrachev; Yu V Korotaeva
Journal:  Dokl Biol Sci       Date:  2014-07-02

2.  PDE2 activity differs in right and left rat ventricular myocardium and differentially regulates β2 adrenoceptor-mediated effects.

Authors:  Fernando Soler; Francisco Fernández-Belda; Joaquín Pérez-Schindler; Christoph Handschin; Teodomiro Fuente; Jesús Hernandez-Cascales
Journal:  Exp Biol Med (Maywood)       Date:  2014-11-27

3.  Activating autoantibodies to the β1/2-adrenergic and M2 muscarinic receptors associate with atrial tachyarrhythmias in patients with hyperthyroidism.

Authors:  Allison Galloway; Hongliang Li; Megan Vanderlinde-Wood; Muneer Khan; Alexandria Benbrook; Campbell Liles; Caitlin Zillner; Veitla Rao; Madeleine W Cunningham; Xichun Yu; David C Kem
Journal:  Endocrine       Date:  2014-12-11       Impact factor: 3.633

4.  Catestatin reverses the hypertrophic effects of norepinephrine in H9c2 cardiac myoblasts by modulating the adrenergic signaling.

Authors:  Md Jahangir Alam; Richa Gupta; Nitish R Mahapatra; Shyamal K Goswami
Journal:  Mol Cell Biochem       Date:  2019-12-02       Impact factor: 3.396

Review 5.  Autonomic nervous system involvement in pulmonary arterial hypertension.

Authors:  Mylène Vaillancourt; Pamela Chia; Shervin Sarji; Jason Nguyen; Nir Hoftman; Gregoire Ruffenach; Mansoureh Eghbali; Aman Mahajan; Soban Umar
Journal:  Respir Res       Date:  2017-12-04

6.  MicroRNA interactome analysis predicts post-transcriptional regulation of ADRB2 and PPP3R1 in the hypercholesterolemic myocardium.

Authors:  Bence Ágg; Tamás Baranyai; András Makkos; Borbála Vető; Nóra Faragó; Ágnes Zvara; Zoltán Giricz; Dániel V Veres; Péter Csermely; Tamás Arányi; László G Puskás; Zoltán V Varga; Péter Ferdinandy
Journal:  Sci Rep       Date:  2018-07-04       Impact factor: 4.379

7.  Binding pathway determines norepinephrine selectivity for the human β1AR over β2AR.

Authors:  Xinyu Xu; Jonas Kaindl; Mary J Clark; Harald Hübner; Kunio Hirata; Roger K Sunahara; Peter Gmeiner; Brian K Kobilka; Xiangyu Liu
Journal:  Cell Res       Date:  2020-10-22       Impact factor: 46.297

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.